Naslov
Profiling colorectal cancer in the landscape personalized testing—advantages of liquid biopsy

Autori
Verbanac, Donatella ; Čeri, Andrea ; Hlapčić, Iva ; Shakibaei, Mehdi ; Brockmueller, Aranka ; Krušlin, Božo ; Ljubičić, Neven ; Baršić, Neven ; Detel, Dijana ; Batičić, Lara ; Rumora, Lada ; Somborac-Bačura, Anita ; Štefanović, Mario ; Ćelap, Ivana ; Demirović, Alma ; Petlevski, Roberta ; Petrik, József ; Grdić Rajković, Marija ; Hulina-Tomašković, Andrea ; Rako, Ivana ; Saso, Luciano ; Barišić, Karmela

Izvornik
International journal of molecular sciences (1422-0067) 22 (2021), 9; 4327, 14

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, pregledni rad, znanstveni

Ključne riječi
biomarkers ; colorectal cancer ; early detection examination ; liquid biopsy ; personalized medicine ; tumor treatment ; exosomes ; ctDNA ; CTC

Sažetak
Drug‐specific therapeutic approaches for colorectal cancer (CRC) have contributed to significant improvements in patient health. Nevertheless, there is still a great need to improve the personalization of treatments based on genetic and epigenetic tumor profiles to maximize the quality and efficacy while limiting cytotoxicity. Currently, CEA and CA 19‐9 are the only validated blood biomarkers in clinical practice. For this reason, laboratories are trying to identify new specific prognostics and, more importantly, predictive biomarkers for CRC patient profiling. Thus, the unique landscape of personalized biomarker data should have a clinical impact on CRC treatment strategies and molecular genetic screening tests should become the standard method for diagnosing CRC. This review concentrates on recent molecular testing in CRC and discusses the potential modifications in CRC assay methodology with the upcoming clinical application of novel genomic approaches. While mechanisms for analyzing circulating tumor DNA have been proven too inaccurate, detecting and analyzing circulating tumor cells and protein analysis of exosomes represent more promising options. Blood liquid biopsy offers good prospects for the future if the results align with pathologists’ tissue analyses. Overall, early detection, accurate diagnosis and treatment monitoring for CRC with specific markers and targeted molecular testing may benefit many patients.

Izvorni jezik
Engleski

Znanstvena područja
Interdisciplinarne prirodne znanosti, Kliničke medicinske znanosti, Farmacija

POVEZANOST RADA